Marizyme Ownership
| MRZM Stock | USD 0.05 0.01 25.00% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Marizyme |
Marizyme OTC Stock Ownership Analysis
The company has price-to-book ratio of 0.37. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Marizyme recorded a loss per share of 0.39. The entity last dividend was issued on the 27th of July 2018. The firm had 1:29 split on the 27th of July 2018. Marizyme, Inc., a life science company, engages in the development and commercialization of medical technologies business. Marizyme, Inc. was incorporated in 2007 and is based in Jupiter, Florida. Marizyme operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 11 people.The quote for Marizyme is listed on Over The Counter exchange (i.e., OTC), and the entity is not required to meet listing requirements such as those found on the Nasdaq, NYSE, or AMEX exchanges. To find out more about Marizyme contact David MBA at 561 935 9955 or learn more at https://marizyme.com.Marizyme Outstanding Bonds
Marizyme issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Marizyme uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Marizyme bonds can be classified according to their maturity, which is the date when Marizyme has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Marizyme OTC Stock
Marizyme financial ratios help investors to determine whether Marizyme OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Marizyme with respect to the benefits of owning Marizyme security.